Thinly traded nano cap Cidara Therapeutics (CDTX +12.5%) is up on more than a 10x surge in volume in early trade in response to a positive outcomefrom Part B of its Phase 2 STRIVE study evaluating antifungal rezafungin in patients with candidemia and/or invasive candidiasis.
Part B met all objectives for efficacy, safety and tolerability.
The company announced positive results from Part A in March.
Detailed data will be presented at an upcoming medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.